One World Pharma announces exclusive cannabis agreement

One World Pharma Inc. (OWP), a fully licensed cannabis and hemp producer in Colombia, is announcing its exclusive partnership with the WALA POPAYAN Cooperative, a highly qualified farming community in the Colombian Andes. Together they will work on the cultivation and refining of hemp-derived ingredients. The company’s offices and operations are located in Bogota and Popayan, Colombia.

This One World Pharma collaboration combines ancestral techniques with modern technology, plant genetics, and international standard operating procedures. 

It is expected to maximize the opportunity for growth in one of the most ideal climates for agriculture in the world. 

About One World Pharma

One World Pharma Inc. is the U.S. parent company of One World Pharma S.A.S. It is a fully licensed cannabis and hemp producer. 

The company’s offices and operations are located in Bogota and Popayan, Colombia. One World Pharma planted its first crop of cannabis in 2018 at its cultivation site in Popayan, Colombia.

The company planted cannabis for research purposes and expects to begin harvesting commercially in the second quarter of 2020.  

Additionally, the company intends to supply the highest quality cannabis and hemp derivatives in crude oil, distillate and isolate forms with industrial-scale production to serve global cannabis demand. Its products will be produced and tested to GMP standards.

OWP’s technological advances, such as genetically modified seeds and seedlings for cannabis cultivation, will help the harvesting and processing of the raw material.

It will also purchase raw biomass, with very high-quality standards and successful laboratory tests. 

Colombia is planning to become the first cannabis country

Colombia’s reputation for premium cannabis precedes it since the country has an excellent location for this. With medical cannabis, the quality does not change but the country’s reputation does.

This change in perception is in lockstep with the broader arc of the changing medical marijuana narrative, fueled by the increased education on the therapeutic merits of the plant to treat everything from dry skin to epileptic seizures to chronic pain.

The weather, soil, and infrastructure, inclusive of a workforce skilled in agriculture, helps keep production cost substantially lower. 

According to Colombia Cannabis Investor, dried flower cannabis can be produced in Colombia for about $0.50 to $0.80 per gram in comparison to about $2 per gram in the U.S.

One World Pharma hopes to begin commercial harvesting in 2020

The aim is for these products to be used in the consumption of packaged and over-the-counter products worldwide.

At the same time, the purpose of the association is to offer a better life for people and for all of Colombia. This includes indigenous communities and small farmers. 

One World Pharma Inc. is the U.S. parent company of One World Pharma S.A.S., a fully licensed producer of cannabis. Its offices and operations are located in Bogotá and Popayán, Colombia. 

Cannabis is a commodity

One World Pharma believes that the future of cannabis is as a commodity, similar to coffee beans or orange juice which are grown and sold to major consumer brands. 

While other cannabis companies have focused on being vertical players spanning from seed to customer-facing dispensaries, One World Pharma is a pure-play cannabis business focused on one thing: supplying high-quality cannabis-derived ingredients to consumer brands. 

The upcoming launch of its “Cannabis Futures” program will provide these brands with predictable pricing for consistent, high-quality cannabis ingredients.

__

(Featured image by Matthias Zomer via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in AMBCRYPTO, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.